Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug

As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin